Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA

KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This multicenter, single-arm, open-label, early exploratory clinical study is designed to evaluate the preliminary safety and efficacy of KSVCBD injection in patients with relapsed or refractory (r/r) B-cell non-Hodgkin's lymphoma (NHL) CD19 and/or BCMA.

Trial Details

NCT ID
NCT07620314
Phase
PHASE1
Sponsor
Chinese PLA General Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • KSVCBD injection
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Age 18-75 years (inclusive), any gender.
  • Subjects must meet the following diagnostic and treatment criteria:
  • 1Histologically or cytologically confirmed B-NHL (according to the 2016 WHO classification of lymphoid neoplasms):
  • Diffuse large B-cell lymphoma, not otherwise specified.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →